PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6152277

Beta-adrenergic blockade alone does not decrease renal perfusion in black hypertensives.

D C Brater·S Anderson·N M Kaplan·C V Ram
View original source ↗Export metadata ↓

Abstract

We assessed the effects on renal haemodynamics in 18 black patients with essential hypertension of acute and chronic beta-adrenergic blockade with three agents having different properties: atenolol, nadolol or propranolol. Six patients received each drug. In our patients the antihypertensive response to beta-blockers was minimal or nonexistent. This permitted us to analyse the effects on renal haemodynamics of 'pure' beta-blockade, as opposed to the combined effects of beta-blockade and decreased systemic perfusion pressure. In this setting, neither acute nor chronic administration (two months) of each of these agents decreased renal perfusion. We conclude, therefore, that beta-blockade per se has no deleterious effect on renal function and previous observations are most probably accounted for by the blood pressure lowering effect of these drugs, either alone or coupled with beta-blockade of the renal vasculature allowing unopposed alpha-sympathetically mediated vasoconstriction.

Explore related subjects

Adrenergic beta-AntagonistsAtenololBlood PressureGlomerular Filtration RateHeart RateHumansHypertensionKidneyMaleNadololPropanolaminesPropranololReninJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D C Brater, S Anderson, N M Kaplan, C V Ram. 1984. Beta-adrenergic blockade alone does not decrease renal perfusion in black hypertensives.. https://doi.org/10.1097/00004872-198402000-00008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Beta-adrenergic blockers as cardioprotective agents.

The evidence supporting and describing cardioprotective effects of beta-adrenergic blocker treatment is surveyed. Details of the many studies that individually and collectively document the ability of long-term and acute beta-blocker therapy to reduce overall mortality, sudden cardiovascular death, and nonfatal reinfarction in patients surviving or experiencing a myocardial infarction are described. A discussion of the mechanisms by which beta blockers probably and theoretically achieve these benefits includes the suggestion that they may reduce plaque rupture, thus indirectly inhibiting thrombosis. It is also suggested that, in the future, further cardioprotective benefits may accrue to the use of beta blockers in conjunction with thrombolysis and of beta blockers with a duration of action sustained throughout a full 24 hours.

Adrenergic beta-Antagonists↗
PubMed1992

[Developments in the treatment of myocardial infarction in Switzerland 1986-1990: results of a population survey].

The Swiss cantons of Vaud and Fribourg participate in the international MONICA project (MONI-toring of trends and determinants in CArdiovascular disease). Within this context, drug therapies and procedures were recorded during two separate years (1986 and 1990) for all hospitalizations of men aged 25 to 64 with the diagnosis of myocardial infarction. The medical files were reviewed to classify this diagnosis as possible or definite on the basis of the symptoms, the ECG results and the enzymatic tests. The two study populations (n = 318 in 1986 and n = 332 in 1990) are comparable with respect to age, history of ischemic heart disease and initial care. In 1990, half of the patients arrived at hospital in less than 3 hours, the median time delay being 4 hours for those first attending a general practitioner and 2 hours for those transferred directly. The frequency of treatments between 1986 and 1990 is compared only for cases with a definite diagnosis of myocardial infarction (respectively n = 217 and n = 223). The proportion of patients given thrombolytic therapy rose from 9% to 44% (p < 0.005) and from 51% to 95% (p < 0.005) for those treated with antiplatelet drugs, whereas the proportion fell from 72% to 55% (p < 0.005) for calcium blockers and from 33% to 24% (p < 0.05) for inotropic drugs. The use of anticoagulants (in 98% of patients) and of beta blockers (in 57%) remained stable across time.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗